Skip to main
ARCT
ARCT logo

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Arcturus Therapeutics Holdings Inc has demonstrated promising clinical progress with the RT-810 treatment, evidenced by statistically significant improvements in glutamine levels and 15N urea, showcasing its potential efficacy with a clean safety profile. Additionally, positive trends in exploratory endpoints such as HRCT lung scans and FEV1 measures indicate beneficial responses in key patient populations, enhancing the therapeutic prospects of their pipeline candidates, including LUNAR-OTC and LUNAR-CF. The company's strong intellectual property defense strategy further bolsters its growth outlook, suggesting that Arcturus may capitalize on its innovations more effectively than anticipated.

Bears say

The financial outlook for Arcturus Therapeutics is negatively impacted by the disappointing interim data from its ARCT-032 trial, which failed to show a meaningful improvement in FEV1, leading to the removal of this asset from the company's valuation model. Furthermore, the company faces significant downside risks related to the potential delays in clinical trial initiation or enrollment for key pipeline products, along with concerns over unexpected safety issues or lower-than-expected efficacy. Lastly, the company's ability to protect its patents remains questionable, posing additional threats from increased generic competition, which has prompted a substantial reduction in the price target by financial analysts.

Arcturus Therapeutics (ARCT) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 8 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.